Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XTR003 + 18F-FDG
- Development stage
- Preclinical
- Lead developer
- Sinotau Pharmaceutical Group
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
XTR003 + 18F-FDG is a **combination diagnostic imaging agent** used in positron emission tomography (PET). **18F-FDG** (fludeoxyglucose F 18) is a radiolabeled glucose analog that accumulates in cells with high glucose metabolism, notably cancer cells, and is widely used as a PET imaging tracer in oncology, cardiology, and neurology[2][3][4][5]. XTR003 is a code name for an investigational agent; however, its specific mechanism, chemical identity, and development status are not characterized in available literature. The combination is intended to improve imaging by targeting both metabolic and possibly additional pathological features, but the mechanism specifically attributed to XTR003 is not described in the available data.
- Other names
- fludeoxyglucose F 18fluorodeoxyglucose F 18FDG
02
Targets
GLUT (Glucose transporter family)GCK (Glucokinase)GLUT1 (Glucose transporter 1)SLC2A3 (Glucose transporter type 3)
Beyond the preview
Go deeper on XTR003 + 18F-FDG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XTR003 + 18F-FDG.